Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2014 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Identifier:
First received: September 29, 2010
Last updated: November 11, 2014
Last verified: May 2014


- TessArray Resequencing Pathogen Microarray is a new technology that can identify multiple infectious agents in a single specimen. Researchers are interested in determining whether the technology can accurately identify the germs responsible for causing respiratory infections. Respiratory samples, such as sputum or cells and fluid from the lungs, will be collected and studied using this technique.


- To evaluate the effectiveness of using TessArray Resequencing Pathogen Microarray to examine and identify infectious agents in respiratory samples.


- Individuals at least 2 years of age who are having respiratory samples collected as part of a doctor's evaluation.


  • Participants will be selected from individuals who are providing respiratory samples as part of treatment for an infection or for other medical reasons. A portion of the respiratory sample collected will be used for research purposes.
  • Participants will provide a blood sample during or up to 3 days before or after the collection of the respiratory sample.
  • Participants may be asked to provide a second blood sample 2 to 12 weeks after the first sample is taken.
  • Treatment will not be provided as part of this study.


Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Multiplex Microarray Chip-Based Diagnosis of Respiratory Infections

Resource links provided by NLM:

Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • The sensitivity, compared to standard microbiological methods, of a customized TessArray microarray for the diagnosis of respiratory infections. [ Time Frame: At time of enrollment ] [ Designated as safety issue: No ]

Estimated Enrollment: 250
Study Start Date: September 2010
Detailed Description:

Respiratory infections have a high associated morbidity and mortality, especially in immunocompromised patients. To initiate effective treatment of respiratory infections, it is essential that a rapid and thorough laboratory analysis of respiratory specimens be performed, given the wide range of pulmonary pathogens that can be detected in this population. Conventional microbiology is time-consuming and cumbersome, and the capability of local laboratories to assess specimens for rare or unusual pathogens is often limited. This study will evaluate if a newer technology can be effectively utilized in the identification of a broader range of infectious agents relative to conventional procedures.

The TessArray -Resequencing Pathogen Microarray (RPM) technology (from TessArae , LLC) uses a microarray chip to identify multiple pathogens in a clinical specimen. The technology has had limited clinical application, but early studies have shown its effectiveness in accurately identifying a large number of viral and bacterial organisms. In contrast to conventional microbiological procedures based on phenotypic traits (growth characteristic and enzymatic activity), the TessArray microarray utilizes DNA sequence analysis to detect and identify the species, serotype/subtype, or strain of the infectious agent.

Aliquots of respiratory specimens (initially, specimens collected by bronchoalveolar lavage, BAL) from 200 patients at the NIH Clinical Center and the Washington Hospital Center will be analyzed using the TessArray microarray. The specimens will be collected as part of the patients routine clinical care. The results of the TessArray microarray analysis will not be available to the clinician and therefore will not have any effect on the clinical care of the patients.

The results of the TessArray microarray analysis from each site will be compared to that site s clinical laboratory results, and the data will be analyzed by site.


Ages Eligible for Study:   2 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Subjects may be included in this study if they:

  1. Are 2 years of age and older.
  2. Are being evaluated for a respiratory infection.
  3. Are having respiratory specimens collected as part of their clinical evaluation.
  4. Agree to have specimens stored for future research.


Patients unable or unwilling to give informed consent will be excluded from the study.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01212042

Contact: Maryellen McManus, R.N. (301) 451-4647
Contact: Joseph A Kovacs, M.D. (301) 496-9907

United States, District of Columbia
Washington Hospital Center Recruiting
Washington, District of Columbia, United States, 20010
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike Recruiting
Bethesda, Maryland, United States, 20892
Contact: For more information at the NIH Clinical Center contact Patient Recruitment and Public Liaison Office (PRPL)    800-411-1222 ext TTY8664111010   
Sponsors and Collaborators
Principal Investigator: Joseph A Kovacs, M.D. National Institutes of Health Clinical Center (CC)
  More Information

Additional Information:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Allergy and Infectious Diseases (NIAID) ) Identifier: NCT01212042     History of Changes
Other Study ID Numbers: 100200, 10-CC-0200
Study First Received: September 29, 2010
Last Updated: November 11, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Pulmonary Pathogens
Immunocompromised Host
Respiratory Infection

Additional relevant MeSH terms:
Respiratory Tract Infections
Respiratory Tract Diseases processed this record on April 16, 2015